| Value | ₹49.50 Cr |
|---|---|
| Execution period | Indicative completion by 31 March 2027, in tranches |
BSE filing, NSE: LALPATHLAB. Summary written from the filing by ALFA Finder's alert engine.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹2,045.00
- Market cap
- ₹34,325 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 58.8×Sector 53.8×
- Promoter holding
- 52.93%-0.26% QoQ
- FII holding
- 18.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Management Change
Dr. Lal Path Labs appointed Ms. Vasuta Agarwal as an additional Non-Executive Independent Director for three years from 4 November 2026. Her appointment is subject to member approval by postal ballot.
- Execution
- 36 months from 04-11-2026
Dr. Lal Pathlabs Dividend
Dr. Lal Path Labs approved a Rs 5 per share second interim dividend. Record date is November 11, 2026; payment by December 3, 2026.
Dr. Lal Pathlabs Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 874 Cr (+19.6%), EBITDA Rs 280 Cr (32.1% margin), PAT Rs 194 Cr (+27.5%). Strategy: AI diagnostics, rural GraminFit, M&A.
Dr. Lal Pathlabs Q2 FY27 Results: Net Profit ₹193.9 Cr, Up 27.4% YoY
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹873.9 Cr (+19.6% YoY) and net profit of ₹193.9 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹193.9 Cr · +27.4% YoY
Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs updated its 4 November 2026 board meeting notice to add a possible second interim dividend. The meeting will also approve unaudited quarterly results.
Dr. Lal Pathlabs Acquisition Worth ₹30.3 Cr
Dr. Lal PathLabs subscribed to WOS PUPL equity to fund PUPL's buyout of remaining 30% in CentraPath Labs for ₹30.3 Crore. CentraPath becomes a wholly owned subsidiary.
- Value
- ₹30.30 Cr
Other capital structure change announcements
All →Arvaya Healthcare Capital Structure Change
Arvaya Healthcare's board approved the draft letter of offer for a rights issue of partly paid-up equity shares up to ₹210 Crore, plus a postal ballot. The board outcome's main decision is the rights issue, so it is classified as a capital raise step.
- Value
- ₹210.0 Cr
Mittal Life Style Capital Structure Change
Mittal Life Style set 15 December 2026 as the record date for a 10:1 consolidation of its equity shares. No cash is paid.
Zodiac JRD MKJ Capital Structure Change
Zodiac-JRD-MKJ approved final terms of its Rs 40 crore rights issue at Rs 25 per share. Issue runs 19 November to 3 December 2026.
- Value
- ₹40.00 Cr
Baba Arts Capital Structure Change
Skybridge Interactive LLP, a non-promoter acquirer, disclosed under Reg 29(2) that it acquired 65,00,000 shares of Baba Arts, raising its stake from 62.28% to 74.67%. The acquisition was off-market under a share purchase agreement dated 25 February 2026.
Atul Capital Structure Change
Atul bought back 4,100 equity shares on 4 November 2026 for ₹2.09 Crore. Cumulative buyback utilisation stands at ₹10.82 Crore of ₹90 Crore earmarked.
- Value
- ₹2.09 Cr
Jenburkt Pharmaceuticals Capital Structure Change
Counter Cyclical Investments Private Limited acquired 4,608 equity shares of Jenburkt Pharmaceuticals Ltd through the open market. This acquisition increased the acquirer's total holding from 5.01% to 5.11%.